LIGHT

CompletedPhase 2

A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients

A Randomized, Double-Blind, Placebo-controlled Study of Efsubaglutide Alfa on Weight Management in Subjects With Overweight or Obesity to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics, and Efficacy.

Lead sponsor

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Asset

Efsubaglutide Alfa

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥28

Primary endpoints

•Weight•Adverse Event

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06732960

Org study IDYN011-W201

Timeline

Milestones

Study start2024-04-21actual

Primary completion2024-11-18actual

Study completion2024-11-18actual

Study first posted2024-12-13actual

Last update posted2025-04-02actual

Assets

Investigational agents

Efsubaglutide Alfa

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Fully understood the study, signed the informed consent.

•Male or female patients aged from 18 to 75 years at the time of signing informed consent.

•Body mass index (BMI) greater than or equal to 28 kg/sqm or greater than or equal to 24 kg/sqm with the presence of at least one of the following weight-related comorbidities: prediabetic state, hypertension, dyslipidemia, non-alcoholic steatohepatitis (NASH), obstructive sleep apnea or cardiovascular disease.

•A self-reported change in body weight less than 5% within 90 days before screening irrespective.

Exclusion criteria

•Glycated hemoglobin (HbA1c) greater than or equal to 6.5%, or previously diagnosed with type 1 diabetes or type 2 diabetes.

•Have history of clinically significant abnormal gastric emptying, severe chronic gastrointestinal diseases, long-term use of medications that directly affect gastrointestinal peristalsis, or gastrointestinal surgery within 6 months prior to screening, and deemed unsuitable for participation by the investigator.

•Have history of hyperthyroidism or hypothyroidism, or a thyroid-stimulating hormone (TSH) level below the lower limit or above 1.5 times the upper limit of the normal range.

•Calcitonin greater than or equal to 50 ng/L, or have history of medullary thyroid carcinoma, multiple endocrine neoplasia (MEN) type 2A or 2B syndrome, or a related family history.

•Any other condition that, in the judgment of the researchers, may affect the patient's ability to provide informed consent or comply with the trial protocol.

Endpoints (17)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Weight & body composition

Glycemic / diabetes

Other (unclassified)

Safety / tolerability / PK

Weight & body composition

5 endpoints

Primary/protocol endpoint

Weight

Time frame:Baseline, 4 weeks after the target dose

descriptive

Secondary/protocol endpoint

Weight

Time frame:Baseline, 4 weeks after the target dose

descriptive

Secondary/protocol endpoint

BMI

Time frame:Baseline, 4 weeks after the target dose

descriptive

Secondary/protocol endpoint

Waist circumference

Time frame:Baseline, 4 weeks after the target dose

descriptive

Secondary/protocol endpoint

Waist Hip Rate (WHR)

Time frame:Baseline, 4 weeks after the target dose

descriptive

Glycemic / diabetes

3 endpoints

Secondary/protocol endpoint

HbA1c

Time frame:Baseline, 4 weeks after the target dose

descriptive

Secondary/protocol endpoint

Fasting Blood Insulin

Time frame:Baseline, 4 weeks after the target dose

descriptive

Secondary/protocol endpoint

HOMA-IR

Time frame:Baseline, 4 weeks after the target dose

descriptive

Cardiometabolic biomarkers

6 endpoints

Secondary/protocol endpoint

Diastolic pressure

Time frame:Baseline, 4 weeks after the target dose

descriptive

Secondary/protocol endpoint

Systolic pressure

Time frame:Baseline, 4 weeks after the target dose

descriptive

Secondary/protocol endpoint

Triglyceride

Time frame:Baseline, 4 weeks after the target dose

descriptive

Secondary/protocol endpoint

Total Cholesterol

Time frame:Baseline, 4 weeks after the target dose

descriptive

Secondary/protocol endpoint

High Density Lipoprotein Cholesterol （HDL-C）

Time frame:Baseline, 4 weeks after the target dose

descriptive

Secondary/protocol endpoint

Low-Density Lipoprotein Cholesterol （LDL-C）

Time frame:Baseline, 4 weeks after the target dose

descriptive

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Adverse Event

Time frame:Adverse events occurring within 4 weeks of the last dose from baseline

descriptive

Other (unclassified)

2 endpoints

Secondary/protocol endpoint/low confidence

Hip circumference

Time frame:Baseline, 4 weeks after the target dose

descriptive

Secondary/protocol endpoint/low confidence

Body Fat

Time frame:Baseline, 4 weeks after the target dose

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.